ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2265

Lupus Damage Index Revision – Item Generation and Reduction Phase

Burak Kundakci1, Megan Barber2, Ann Clarke2, Sindhu Johnson3, Ian Bruce4 and On behalf of the revised SLE organ damage index (SDI) collaborators4, 1Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, 2University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 3Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 4University of Manchester, Manchester, United Kingdom

Meeting: ACR Convergence 2023

Keywords: Damage Index, Outcome measures, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The SDI is a robust instrument, but is limited by incomplete items, restricted applicability in paediatric patients, and outdated item definitions1. The SLICC, ACR and LFA have embarked on a data- and expert/patient-driven project to develop a revised SDI. Our objective was to report the item generation and reduction phases of a five-phase process for developing a revised SDI.

Methods: Item generation and reduction involved a thorough literature review, a three-round Delphi exercise, and a subsequent revision by a 14-member steering committee. A group of lupus experts conducted a literature review to identify items that reflect the construct of damage in SLE and grouped the items into organ domains. A large international group of expert lupus clinicians was established by snow-ball sampling amongst SLICC members. Patient and caregiver partners were nominated through the LFA, Lupus UK, Lupus Europe, and Lupus Canada.
Participants generated and rated candidate items based on their appropriateness for inclusion in a revised SDI using a Delphi exercise. The 14-member steering committee then reviewed the items for further refinement.

Results: We assembled a diverse group of 146 individuals (mean age 50.6, ranging from 28 to 79 years; 60.3% females; 58.9% white; clinical experience ranging from 1 to 51 years) from 35 countries, representing the lupus research and patient community extensively. There were 135 medical doctors, 2 allied health professionals and 9 patients.
Item generation resulted in a total of 220 items across 14 organ systems. The literature review identified 4 unique items (1.8%), while 103 unique items (46.8%) were derived from the Delphi exercise alone, and 113 items (51.4%) appeared in both exercises. In the second round of the Delphi exercise, participants suggested an additional 6 unique items. Overall, 226 items were subjected to re-rating for appropriateness for inclusion in the revised SDI. Completion rates for the first, second, and third Delphi rounds were 97.9%, 95.0%, and 91.7%, respectively. Thirty-six items received a median score of  4 out of 9 and these were removed. All original 1996 SDI items were retained with median appropriateness scores of 7, 8, and 9, except for upper gastrointestinal tract surgery (median appropriateness score 5) and osteomyelitis (median appropriateness score 5). The steering committee further eliminated 126 items due to redundancy, limited availability or feasibility for assessment, overlap, lack of reflection of damage construct or association with lupus disease activity, and rarity. Figure 1 shows the number of candidate items identified at different stages during revised SDI development.

Conclusion: Using a combined data-driven and expert/patient-based approach, items and domains that comprise damage in SLE have been expanded. The item generation and reduction phase resulted in 64 candidate items for consideration. All original SDI items were retained in this step. Further steps are now underway to agree upon definitions for those items, including extent and duration of item presence, based on the best current evidence and internationally accepted norms.
1) Barber M, et al. Evolving concepts in SLE damage assessment. Nat Rev Rheumatol. 2021;17(6):307-8

Supporting image 1

Figure 1. Number of candidate items identified at different stages of Phase II/III during revised SDI development


Disclosures: B. Kundakci: None; M. Barber: AbbVie/Abbott, 2, AstraZeneca, 2, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, Sanofi Genzyme, 2; A. Clarke: AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2, GlaxoSmithKlein(GSK), 2, 5, Otsuka, 2, Roche, 2; S. Johnson: None; I. Bruce: AstraZeneca, 1, 2, 5, 6, Aurinia, 2, GSK, 1, 2, 5, 6, Janssen, 5, 6, Lilly, 1, UCB, 6; O. organ damage index (SDI) collaborators: None.

To cite this abstract in AMA style:

Kundakci B, Barber M, Clarke A, Johnson S, Bruce I, organ damage index (SDI) collaborators O. Lupus Damage Index Revision – Item Generation and Reduction Phase [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/lupus-damage-index-revision-item-generation-and-reduction-phase/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-damage-index-revision-item-generation-and-reduction-phase/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology